First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

Author(s):

James K. McCloskey, MD, John Theurer Cancer Center,Thomas W. LeBlanc, MD, MA

Panelists discuss how their clinical experience with ESA failure rates and timelines compares with reported outcomes in large community practice studies, and how they counsel patients on the choice between luspatercept and ESAs as first-line therapy for lower-risk MDS, incorporating patient preferences and patient-reported outcomes from recent clinical trials.

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP: 9.Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

Now Viewing

EP: 10.First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP: 11.Imetelstat and IMerge Trial Review

EP: 12.Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 13.The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

Please describe: In your clinical practice, what percentage of your patients have disease that fails ESA? What is the general time frame where you may see ESA failure?
How does this compare with reported ESA outcomes? Resource link: Gordan L, et al. LR-MDS large US community practice: pt outcomes post ESA Tx. EHA 2024 abstract.
Please describe what you typically counsel and/or share with your patients when considering luspatercept vs ESA as first-line therapy for LR-MDS. How do you take into consideration the patient’s preference

Resource link: Olivia EN, et al. Patient-reported outcomes from COMMANDS study. ASH 2023 abstract.